期刊文献+

头孢哌酮舒巴坦治疗脓毒血症可有效降低患者的炎症因子、Pro-ADM、MIF水平 被引量:10

Cefoperazone Sulbactam in Treatment of Sepsis can Effectively Reduce the Levels of Inflammatory Factors, Pro-ADM and MIF
原文传递
导出
摘要 本研究为分析头孢哌酮舒巴坦对脓毒血症患者血清炎症因子变化、临床治疗效果及护理对策,选取了102例自2016年1月至2017年4月我院收治的脓毒血症患者,将研究对象根据治疗方法不同分为对照组和观察组各51例进行研究。对照组患者采用常规对症治疗,观察组患者在对照组的基础上联合头孢哌酮舒巴坦进行治疗,分析两组患者治疗后的临床疗效。治疗前,两组患者IL-1、IL-1β、PCT、CRP、NT-pro BNP、Pro-ADM、MIF水平比较无统计学差异(p〉0.05),治疗后,观察组患者IL-1、IL-1β、PCT、CRP、NT-pro BNP、Pro-ADM、MIF水平低于对照组(p〈0.05);两组患者治疗前后免疫功能指标水平比较均无统计学差异(p〉0.05);治疗前,两组患者APACHEII评分比较无统计学差异(p〉0.05),治疗后,观察组患者APACHEII评分优于对照组(p〈0.05)。研究表明头孢哌酮舒巴坦治疗脓毒血症疗效显著,可降低患者炎症因子、Pro-ADM、MIF水平,同时对机体免疫功能影响较小,安全性较高。 This research is for the purpose of analyzing the effect of cefoperazone sulbactam on serum inflammatory factors in patients with sepsis. The research team had retrospectively chosen 102 patients with sepsis from January 2016 to April 2017. The patients were divided into control group and observation group according to different treatment methods, each group had 51 patients. The patients in control group were treated with routine symptomatic therapy. The patients in the observation group were treated with Cefoperazone sulbactam on the basis of routine symptomatic treatment. Before treatment, there was no significant difference in the level of IL-1, IL-1βand CRP, NT-pro BNP, Pro-ADM and MIF between two groups(p〉0.05). After treatment the level of IL-1, IL-1βand CRP, NT-pro BNP, Pro-ADM and MIF of observation group was lower than that of control group(p〈0.05).There was no significant difference in the level of immune function between the two groups before and after treatment(p〉0.05). Before treatment, there was no significant difference in APACHEII score between the two groups(p〉0.05). After treatment, the APACHEII score in the observation group was better than that in control group(p〈0.05). This research had shown that Cefoperazone sulbactam has a significant therapeutic effect on sepsis,which can reduce the level of Pro-ADMN MIF in patients with sepsis, but has little effect on immune function, as had high security.
作者 刘丽红 王永芳 Liu Lihong;Wang Yongfang(Langfang Halth Vocational College,Langfang,06500)
出处 《基因组学与应用生物学》 CAS CSCD 北大核心 2018年第9期4082-4087,共6页 Genomics and Applied Biology
基金 廊坊卫生职业学院资助
关键词 头孢哌酮舒巴坦 脓毒血症 炎症因子 免疫功能 Cefoperazone sulbactam Sepsis Inflammatory factors Immune function
  • 相关文献

参考文献9

二级参考文献115

  • 1季大玺.连续性血液净化与重症感染[J].肾脏病与透析肾移植杂志,2004,13(3):235-236. 被引量:58
  • 2邱海波.连续血液净化治疗重症感染的体会[J].肾脏病与透析肾移植杂志,2004,13(3):238-239. 被引量:31
  • 3樊寻梅.儿科感染性休克(脓毒性休克)诊疗推荐方案[J].中华儿科杂志,2006,44(8):596-598. 被引量:205
  • 4王建文,彭佑铭,陈星,刘伏友,张浩.连续性血液净化对内皮细胞组织因子活性的影响及相关因素分析[J].中国血液净化,2007,6(2):81-84. 被引量:6
  • 5Gu W,Zeng L,Zhou J,et al.Clinical relevance of 13 cytokine genepolymorphisms in Chinese major trauma patients[J].IntensiveCare Med,2010,36(7):1261-1265.
  • 6Petel A.Bench-to-bedside review:the initial hemodynamic resusci-tation of the septic patient according to Surviving Sepsis Campaignguidelines——does one size fit all?[J].Crit Care,2008,12(5):223.
  • 7Payen D.The efficacy and safety of colloid resuscitation in the crit-ically ill[J].Anesth Analg,2011,112(1):17-18.
  • 8Hartog CS,Kohl M,Reinhart K.A systematic review of third-gener-ation hydroxyethyl starch(HES130/0.4)in resuscitation:safety notadequately addressed[J].Anesth Analg,2011,112(3):635-645.
  • 9James MF,Michell WL,Joubert IA,et al.Resuscitation withhydroxyethyl starch improve renal function and lactate clearance inpenetrating trauma in a randomized controlled study:the FIRST tri-al(Fluid in Resuscitation of Severe Trauma)[J].Br J Anaesth,2011,107(5):693-702.
  • 10Delaney AP,Dan A,McCaffrey J,et al.The role of albumin as a re-suscitation fluid for patients with sepsis:a systematic review andmeta-analysis[J].Crit Care Med,2011,39(2):386-391.

共引文献109

同被引文献104

引证文献10

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部